Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Catholic University of the Sacred Heart
- Target Recruit Count
- 100
- Registration Number
- NCT01772979
- Locations
- 🇮🇹
Catholic University of Sacred Heart, Rome, Italy
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01692678
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
- Conditions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT01427582
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2022-02-09
- Target Recruit Count
- 617
- Registration Number
- NCT01379989
- Locations
- 🇦🇹
Medizinische Universitat Graz, Graz, Austria
🇳🇱Radboud University Medical Centre, Nijmegen, NL, Netherlands
🇳🇴Stavanger University Hospital, Stavanger, Norway
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 579
- Registration Number
- NCT01343277
Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 25
- Registration Number
- NCT01339754
- Locations
- 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy
Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 53
- Registration Number
- NCT01303094
- Locations
- 🇫🇷
Saint-Jacques Hospital, Besancon, France
🇫🇷Centre François Baclesse, Caen, France
🇫🇷Centre Jean Perrin, Clermont Ferrand, France
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01273493
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01267084
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2014-08-08
- Target Recruit Count
- 133
- Registration Number
- NCT01189253
- Locations
- 🇫🇷
ASSISTANCE PUBLIQUE - HôPITAUX DE MARSEILLE - HôPITAL DE LA TIMONE, Marseille, France
🇺🇸Methodist Estabrook Cancer Center, Omaha, Nebraska, United States
🇩🇪Universitaetsklinikum Koeln, Koeln, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.